IL6 and interstitial lung disease: The additional treatments used for those RP-ILD patients without PE were biologics [anti-TNF-α (n = 1) or anti-IL-6 (n = 2)], intravenous immunoglobulin (n = 1), or weekly intravenous CYC (n = 1) [16].